Company: Asher Biotherapeutics Inc.
Job title: Cell Therapy Lead
Selective Cell Type Targeting Improves Anti-tumor Activity and Safety of Cytokines 3:30 pm
Asher Bio’s cis-targeting platform generates cell type selective immunomodulators Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor activity and safety CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor activityRead more
day: Day Two